Autoimmune inner ear disease (Q42127): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
Doença autoimune da orelha interna é uma síndrome clínica de perda auditiva neurossensorial (PANS) bilateral >30dB em uma ou mais frequências que progride ao longo de um período de 3-90 dias. A progressão de PANS >15dB em uma frequência ou >10dB em duas frequências em pelo menos uma orelha deve ser demonstrada. Sintomas vestibulares podem estar presentes em 50% dos pacientes e doença autoimune sistêmica coexiste em 30% dos pacientes.
description / endescription / en
 
Autoimmune inner ear disease (AIED) is a clinical syndrome of bilateral sensorineural hearing loss (SNHL) >30dB at one or more frequencies progressing over a period of 3-90 days. Progression of SNLH >15dB at one frequency or >10dB in two frequencies in at least one ear should be demonstrated. Vestibular symptoms may be present in 50% of patients and systemic autoimmune disease (SAD) coexists in 30% of patients.

Revision as of 08:32, 13 August 2026

Autoimmune inner ear disease (AIED) is a clinical syndrome of bilateral sensorineural hearing loss (SNHL) >30dB at one or more frequencies progressing over a period of 3-90 days. Progression of SNLH >15dB at one frequency or >10dB in two frequencies in at least one ear should be demonstrated. Vestibular symptoms may be present in 50% of patients and systemic autoimmune disease (SAD) coexists in 30% of patients.
Language Label Description Also known as
default for all languages
AB31.5
    English
    Autoimmune inner ear disease
    Autoimmune inner ear disease (AIED) is a clinical syndrome of bilateral sensorineural hearing loss (SNHL) >30dB at one or more frequencies progressing over a period of 3-90 days. Progression of SNLH >15dB at one frequency or >10dB in two frequencies in at least one ear should be demonstrated. Vestibular symptoms may be present in 50% of patients and systemic autoimmune disease (SAD) coexists in 30% of patients.

      Statements